Genocea Biosciences Inc. (NASDAQ:GNCA)’s share price traded down 3% on Tuesday . The company traded as low as $4.05 and last traded at $4.19, with a volume of 210,437 shares. The stock had previously closed at $4.32.

A number of equities analysts have weighed in on the company. Zacks Investment Research upgraded Genocea Biosciences from a “hold” rating to a “buy” rating and set a $4.75 price target for the company in a report on Tuesday. Needham & Company LLC restated a “buy” rating and issued a $15.00 price target on shares of Genocea Biosciences in a report on Friday, April 1st. FBR & Co restated a “buy” rating and issued a $17.00 price target on shares of Genocea Biosciences in a report on Friday, April 1st. Finally, Stifel Nicolaus upped their price target on Genocea Biosciences from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Friday, April 1st. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Genocea Biosciences currently has a consensus rating of “Buy” and a consensus target price of $18.13.

The company’s 50-day moving average is $4.16 and its 200-day moving average is $4.37. The firm’s market capitalization is $120.21 million.

Genocea Biosciences (NASDAQ:GNCA) last posted its quarterly earnings results on Thursday, May 5th. The company reported ($0.35) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.07. On average, equities analysts anticipate that Genocea Biosciences Inc. will post ($1.74) earnings per share for the current year.

A hedge fund recently raised its stake in Genocea Biosciences stock. AWM Investment Company Inc. boosted its position in Genocea Biosciences Inc. (NASDAQ:GNCA) by 45.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 715,000 shares of the company’s stock after buying an additional 222,900 shares during the period. AWM Investment Company Inc. owned 2.54% of Genocea Biosciences worth $3,768,000 as of its most recent filing with the SEC.

Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.